# US 2022/0031871 A1 · Antibodies for chelated radionuclides and clearing agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031871 A1
- Document ID: US20220031871A1
- Status: Published application
- Kind: A1
- Application number: 17/048,072
- Filed: 2019-04-16
- Published: 2022-02-03
- Earliest claimed: 2018-04-16
- Assignees: Hoffmann-La Roche Inc.; Orano Med
- Applicants: Hoffmann-La Roche Inc.; Orano Med SAS
- Inventors: Julien TORGUE; Paul JUREK; Federico ROJAS-QUIJANO; Garry E. KIEFER; Olivier FREYTAG; Christian GERDES; Christian KLEIN; Pablo UMANA; Alexander HAAS; Sofia FROST; Amal SAIDI; Tapan NAYAK
- Web page: https://patentgrep.com/patent/US20220031871A1

## CPC

- A61K 51/0495: {Pretargeting}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61K 51/065: {conjugates with carriers being macromolecules}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1048: {the tumor cell determinant being a carcino embryonic antigen}
- A61K 51/1051: {the tumor cell being from breast, e.g. the antibody being herceptin}
- A61P 35/00: Antineoplastic agents
- C07K 16/2887: {against CD20}
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies, It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and useful in such methods.

## Claims

### Claim 1

A clearing agent comprising dextran or an aminodextran conjugated to a chelating agent selected from DOTAM and a functional variant of DOTAM, wherein said chelating agent is complexed with a metal ion, and said functional variant of DOTAM is according to the following formula:
or a pharmaceutically acceptable salt thereof; wherein
RN is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-7 heterocycloalkyl, C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4-alkyl, C1-7 heteroaryl, and C1-7 heteroaryl-C1-4-alkyl; wherein C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rw groups; and wherein said C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4alkyl, C2-7 heterocycloalkyl, C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4-alkyl, C1-7 heteroaryl, and C1-7 heteroaryl-C1-4-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rx groups;
L1 is independently C1-6 alkylene, C1-6 alkenylene, or C1-6 alkynylene, each of which is optionally substituted by 1, 2, or 3 groups independently selected R1 groups;
L2 is C2-4 straight chain alkylene, which is optionally substituted by an independently selected R1 group; and which is optionally substituted by 1, 2, 3, or 4 groups independently selected from C1-4 alkyl and or C1-4 haloalkyl;
R1 is independently selected from D1-D2-D3, halogen, cyano, nitro, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, amino, C1-6 alkylamino, di-C1-6 alkylamino, C1-4 alkylcarbonyl, carboxy, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, di-C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkoxycarbonyl-(C1-6 alkyl)amino, carbamyl, C1-6 alkylcarbamyl, and di-C1-6 alkylcarbamyl;
each D1 is independently selected from C6-10 aryl-C1-4 alkyl, C1-9 heteroaryl-C1-4 alkyl, C3-10 cycloalkyl-C1-4 alkyl, C2-9 heterocycloalkyl-C1-4 alkyl, C1-8 alkylene, C1-8 alkenylene, and C1-8 alkynylene; wherein said C1-8 alkylene, C1-8 alkenylene, and C1-8 alkynylene are optionally substituted by 1, 2, 3, or 4 independently selected R4 groups; and wherein said C6-10 aryl-C1-4 alkyl, C1-9 heteroaryl-C1-4 alkyl, C3-10 cycloalkyl-C1-4 alkyl, C2-9 heterocycloalkyl-C1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R5 groups;
each D2 is independently absent or C1-20 straight chain alkylene, wherein from 1 to 6 non-adjacent methylene groups of said C1-20 straight chain alkylene are each optionally replaced by an independently selected -D4- moiety, provided that at least one methylene unit in said C1-20 straight chain alkylene is not optionally replaced by a -D4- moiety; wherein said C1-20 straight chain alkylene is optionally substituted by one or more groups independently selected from halogen, cyano, nitro, hydroxyl, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino, C1-4 alkylcarbonyl, carboxy, C1-4 alkoxycarbonyl, C1-4 alkylcarbonylamino, di-C1-4 alkylcarbonylamino, C1-4 alkoxycarbonylamino, C1-4 alkoxycarbonyl-(C1-4 alkyl)amino, carbamyl, C1-4 alkylcarbamyl, and di-C1-4 alkylcarbamyl;
each D3 is independently selected from H, halogen, cyano, nitro, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-14 cycloalkyl, C3-14 cycloalkyl-C1-4 alkyl, C2-14 heterocycloalkyl, C2-14 heterocycloalkyl-C1-4 alkyl, C6-14 aryl, C6-14 aryl-C1-4 alkyl, C1-13 heteroaryl, C1-13 heteroaryl-C1-4 alkyl; wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R6 groups; and wherein said C3-14 cycloalkyl, C3-14 cycloalkyl-C1-4 alkyl, C2-14 heterocycloalkyl, C2-14 heterocycloalkyl-C1-4 alkyl, C6-14 aryl, C6-14 aryl-C1-4 alkyl, C1-13 heteroaryl, C1-13 heteroaryl-C1-4 alkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R7 groups;
each D4 is independently selected from —O—, —S—, —NRaC(═O)—, —NRaC(═S)—, —NRbC(═O)NRc—, —NRbC(═S)NRc—, —S(═O)—, —S(═O)2—, —S(═O)NRa—, —C(═O)—, —C(═S)—, —C(═O)O—, —OC(═O)NRa—, —OC(═S)NRa—, —NRa—, —NRbS(═O)NRc—, and NRbS(═O)2NRO—;
each R4 and R6 is independently selected from halogen, cyano, nitro, hydroxyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, amino, C1-4 alkylamino, di-C1-4 alkylamino, C1-4 alkylcarbonyl, carboxy, C1-4 alkoxycarbonyl, C1-4 alkylcarbonylamino, di-C1-4 alkylcarbonylamino, C1-4 alkoxycarbonylamino, C1-4 alkoxycarbonyl-(C1-4 alkyl)amino, carbamyl, C1-4 alkylcarbamyl, and di-C1-4 alkylcarbamyl;
each R5 is independently selected from halogen, cyano, cyanate, isothiocyanate, nitro, hydroxyl, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, amino, C1-4 alkylamino, di-C1-4 alkylamino, C1-4 alkylcarbonyl, carboxy, C1-4 alkoxycarbonyl, C1-4 alkylcarbonylamino, di-C1-4 alkylcarbonylamino, C1-4 alkoxycarbonylamino, C1-4 alkoxycarbonyl-(C1-4 alkyl)amino, carbamyl, C1-4 alkylcarbamyl, and di-C1-4 alkylcarbamyl;
each R7 is independently selected from halogen, cyano, nitro, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-7 heterocycloalkyl, C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4 alkyl, C1-7 heteroaryl, C1-7 heteroaryl-C1-4 alkyl, —ORO, —SRO, —S(═O)RP, —S(═O)2RP, —S(═O)NRsRt, —C(═O)RP, —C(═O)ORP, —C(═O)NRsRt, —OC(═O)RP, —OC(═O)NRsRt, —NRsRt, —NRqC(═O)Rr, —NRqC(═O)ORr, —NRqC(═O)NRr, —NRqS(═O)2Rr, and —NRPS(═O)2NRsRt; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected R′ groups; and wherein said C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-7 heterocycloalkyl, C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4 alkyl, C1-7 heteroaryl, C1-7 heteroaryl-C1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R″ groups;
each Ra, Rb, and Rc is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-7 heterocycloalkyl, C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4 alkyl, C1-7 heteroaryl, C1-7 heteroaryl-C1-4 alkyl; wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rw groups; and wherein said C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-7 heterocycloalkyl,
C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4 alkyl,
C1-7 heteroaryl, C1-7 heteroaryl-C1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rx groups;
each Ro, Rp, Rq, Rr, Rs and Rt is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-7 heterocycloalkyl, C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4 alkyl, C1-7 heteroaryl, C1-7 heteroaryl-C1-4 alkyl; wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl are each optionally substituted by 1, 2, 3, or 4 independently selected Ry groups; and wherein said C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-7 heterocycloalkyl, C2-7 heterocycloalkyl-C1-4 alkyl, phenyl, phenyl-C1-4 alkyl, C1-7 heteroaryl, C1-7 heteroaryl-C1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rz groups;
each R′, Rw and Ry is independently selected from hydroxyl, cyano, nitro, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino, and di-C1-4 alkylamino; and
each R″, Rx, and Rz is independently selected from hydroxyl, halogen, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, amino, C1-4 alkylamino, and di-C1-4 alkylamino;
provided that the valency of each atom in the optionally substituted moieties is not exceeded.

### Claim 2 (depends on 1)

The clearing agent of claim 1, which is a compound of the following formula:
dextran-(linker-(M-DOTAM))x
wherein
dextran is dextran or an aminodextran thereof;
linker is a linking moiety;
M-DOTAM is DOTAM or said functional variant thereof incorporating a metal ion; and
x≥1.

### Claim 3 (depends on 1)

The clearing agent of claim 1, wherein x is 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, or 50 or more.

### Claim 4 (depends on 2)

The clearing agent of claim 2, wherein the linking moiety is a bivalent group of the following formula:
where y is 1 to 6, * represents the point of attachment to the dextran, and ** represents the point of attachment to a ring atom of DOTAM or said functional variant thereof.

### Claim 5 (depends on 1)

The clearing agent of claim 1, wherein the aminodextran substituted with one or more groups selected from an amino acid and a saccharide other than glucose.

### Claim 6 (depends on 1)

The clearing agent of claim 1, wherein the number of DOTAM groups as a percentage of the number of glucose units of the dextran or aminodextran is at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 5%.

### Claim 7 (depends on 1)

The clearing agent of claim 1, wherein the average molecular weight of the dextran is 200-800 kDa, optionally greater than 300, 350, 400 or 450 kDa, and optionally less than 700, 650, 600 or 550 kDa, optionally about 500 kDa.

### Claim 8 (depends on 7)

The clearing agent of claim 7, wherein
dextran components or clearing agents of less than a molecular weight cut-off have been removed, wherein the molecular weight cut-off is 50 kDa or above, 100 kDa or above or 200 kDa or above.

### Claim 9 (depends on 8)

The clearing agent of claim 8, wherein the molecular weight cut-off is in the range 50 kDa-250 kDa or 50 kDa-200 kDa, optionally 100 kDa-200 kDa and optionally about 100 kDa, 150 kDa or 200 kDa.

### Claim 10 (depends on 7)

The clearing agent of claim 7, wherein the average molecular weight is 450 kDa-550 kDa, e.g., about 500 kDa.

### Claim 11 (depends on 1)

The clearing agent of claim 1, wherein the metal ion is a stable isotope or an essentially stable isotope.

### Claim 12 (depends on 1)

The clearing agent of claim 1, wherein the metal ion is a Pb, Bi or Ca ion.

### Claim 13 (depends on 1)

A method of preparing a clearing agent comprising:
conjugating a dextran or aminodextran to DOTAM or a functional variant or derivative thereof as defined in claim 1, wherein the method involves chelating DOTAM with a metal ion before and/or after conjugation of DOTAM to the dextran.

### Claim 14 (depends on 13)

The method of claim 13, wherein the metal ion is a stable or essentially stable metal ion.

### Claim 15 (depends on 13)

The method of claim 13, wherein the metal ion is a Pb, Bi or Ca ion.

### Claim 16 (depends on 13)

The method of claim 13, wherein prior to conjugation the dextran or aminodextran is subject to a filtration step to remove species below a molecular weight cut-off/threshold of 50 kDa or above, 100 kDa or above or 200 kDa or above, and/or wherein
the method comprises subjecting the conjugate to a filtration step to remove species below a molecular weight cut-off/threshold of 50 kDa or above, 100 kDa or above or 200 kDa or above.

### Claim at position 17

17-19. (canceled)

### Claim 20 (depends on 1)

A method of pre-targeted radioimaging comprising:
i) administering to the subject a multispecific or bispecific antibody comprising at least one antigen binding site specific for a Pb-DOTAM chelate and at least one antigen binding site specific for a target antigen, wherein following administration the antibody binds to the target antigen and localises to the surface of a cell expressing the target antigen;
ii) administering a clearing agent according to claim 1, wherein the clearing agent is capable of binding to the antibody at the binding site for the Pb-DOTAM chelate and increases clearance of antibody and/or blocks the antigen binding site of antibody not localised to the surface of the cell;
iii) subsequently administering a complex comprising DOTAM or a functional variant thereof as defined in claim 1 chelated with a Pb radioisotope, wherein said complex binds to antibody localised at the surface of the cell; and optionally further comprising
iv) imaging the tissue or organ where the chelated radionuclide has localized.

### Claim 21 (depends on 1)

A method of pre-targeted radioimmunotherapy comprising:
i) administering to the subject a multispecific or bispecific antibody comprising at least one antigen binding site specific for a Pb-DOTAM chelate and at least one antigen binding site specific for a target antigen, wherein following administration the antibody binds to the target antigen and localises to the surface of a cell expressing the target antigen;
ii) administering a clearing agent according to claim 1, wherein the clearing agent is capable of binding to the antibody at the binding site for the Pb-DOTAM chelate and increases clearance of antibody and/or blocks the antibody binding site of antibody not localised to the surface of the cell; and
iii) subsequently administering a complex comprising DOTAM or a functional variant thereof as defined in claim 1 chelated with a Pb radioisotope, wherein said complex binds to the antibody localised at the surface of the cell.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the antigen binding site specific for the Pb-DOTAM chelate comprises at least:
a) a heavy chain CDR1;
b) a heavy chain CDR2 comprising the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO:2), or a variant thereof having up to 1, 2, or 3 substitutions in SEQ ID NO: 2, wherein these substitutions do not include Phe50, Asp56 and Tyr58, and optionally also do not include Gly52 and/or Arg 54;
c) a heavy chain CDR3 comprising the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO:3), or a variant thereof having up to 1, 2, or 3 substitutions in SEQ ID NO: 3, wherein these substitutions do not include Glu95, Arg96, Asp97, Pro98, and optionally also do not include Ala100C, Tyr100D, and/or Pro100E and/or optionally also do not include Tyr99;
d) a light chain CDR1 comprising the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO:4) or a variant thereof having up to 1, 2, or 3 substitutions in SEQ ID NO: 4, wherein these substitutions do not include Tyr28 and Asp32;
e) a light chain CDR 2; and
f) a light chain CDR3 comprising the amino acid sequence LGGYDDESDTYG (SEQ ID NO:6) or a variant thereof having up to 1, 2, or 3 substitutions in SEQ ID NO: 6, wherein these substitutions do not include Gly91, Tyr92, Asp93, Thr95c and Tyr96, wherein numbering is according to Kabat.

### Claim 23

(canceled)

### Claim 24 (depends on 22)

The method according to claim 22, wherein the antigen binding site specific for the Pb-DOTAM chelate comprises:
i) a heavy chain CDR1 comprising the amino acid sequence GFSLSTYSMS (SEQ ID NO:1) or a variant thereof having up to 1, 2, or 3 substitutions in SEQ ID NO: 1, optionally conservative substitutions; and/or
ii) a light chain CDR2 comprising the amino acid sequence QASKLAS (SEQ ID NO: 5) or a variant thereof having at least 1, 2 or 3 substitutions in SEQ ID NO: 5, optionally conservative substitutions.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the antigen binding site specific for the Pb-DOTAM chelate comprises at least one, two, three, four, five, or six CDRs selected from:
a) a heavy chain CDR1 comprising the amino acid sequence GFSLSTYSMS (SEQ ID NO:1);
b) a heavy chain CDR2 comprising the amino acid sequence
(SEQ ID NO: 2)
FIGSRGDTYYASWAKWG;
c) a heavy chain CDR3 comprising the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO:3);
d) a light chain CDR1 comprising the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO:4);
e) a light chain CDR2 comprising the amino acid sequence QASKLAS (SEQ ID NO: 5); and
f) a light chain CDR3 comprising the amino acid sequence LGGYDDESDTYG (SEQ ID NO:6).

### Claim 26

(canceled)

### Claim 27 (depends on 21)

The method according to claim 21, wherein the antigen binding site specific for the Pb-DOTAM chelate is human, chimeric or humanized.

### Claim 28 (depends on 21)

The method according to claim 21, wherein the antigen binding site specific for the Pb-DOTAM chelate comprises
i) a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7 and SEQ ID NO 9, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 7 or SEQ ID NO: 9; and/or
ii) a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 10, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 8 or 10.

### Claim 29

(canceled)

### Claim 30 (depends on 21)

The method according to claim 21, wherein the antigen binding site specific for the Pb-DOTAM chelate comprises
i) a heavy chain variable domain comprising an amino acid sequence of SEQ ID No. 7 and a light chain variable domain comprising an amino acid sequence of SEQ ID NO. 8; or
ii) a heavy chain variable domain comprising an amino acid sequence of SEQ ID No. 9 and a light chain variable domain comprising an amino acid sequence of SEQ ID NO. 10.

### Claim at position 29

31-33. (canceled)

### Claim 34 (depends on 21)

The method according to claim 21, wherein the target antigen is a tumour specific antigen.

### Claim 35 (depends on 21)

The method according to claim 21, wherein the tumour specific antigen is selected from the group consisting of CEA, HER2 and CD20.

### Claim at position 32

36-46. (canceled)

### Claim 47 (depends on 21)

The method according to claim 21, wherein the multispecific or bispecific antibody comprises an Fc region.

### Claim 48 (depends on 47)

The method according to claim 47, wherein the Fc region is engineered to reduce effector function.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the Fc region is engineered by substitution of one or more of residues 234, 235, 238, 265, 269, 270, 297, 327 and/or 329.

### Claim at position 36

50-53. (canceled)

### Claim 54 (depends on 47)

The method according to claim 47, wherein the multispecific or bispecific antibody comprises
i) a full length antibody comprising an antigen binding site for a first antigen, and
ii) at least a second heavy chain variable domain and second light chain variable domain which together form an antigen binding site for a second antigen, wherein either the first or the second antigen is the Pb-DOTAM chelate, and the other is the target antigen.

### Claim 55 (depends on 54)

The method according to claim 54, wherein the multispecific or bispecific antibody comprises a full length antibody comprising an antigen binding site for the first antigen, wherein the N- or C-terminus of one of the heavy chains is linked via a polypeptide linker to a first polypeptide and wherein the first polypeptide associates with a second polypeptide to form a Fab or a cross-Fab comprising a binding site for the second antigen.

### Claim 56 (depends on 55)

The method according to claim 55, wherein the multispecific or bispecific antibody comprises:
i) a first polypeptide consisting of a VH domain and a CH1 domain, which is associated with a second polypeptide consisting of a VL and CL domain; or
ii) a first polypeptide consisting of a VL domain and a CH1 domain, which is associated with a second polypeptide consisting of a VH and CL domain; or
iii) a first polypeptide consisting of a VH domain and a CL domain, which is associated with a second polypeptide consisting of a VL and CH1 domain;
such that the first and second polypeptide together form an antigen binding site for a second antigen.

### Claim 57 (depends on 56)

The method according to claim 56, wherein the multispecific or bispecific antibody comprises a full length antibody comprising an antigen binding site for the first antigen, wherein the C-terminus of one of the heavy chains is linked via a polypeptide linker to a first polypeptide consisting of a VL domain and a CH1 domain, which is associated with a second polypeptide consisting of a VH and CL domain.

### Claim at position 41

58-66. (canceled)

### Claim 67 (depends on 1)

The clearing agent of claim 1, wherein each RN is H, C1-6 alkyl, or C1-6 haloalkyl; each L1 is C1-4 alkylene; and each L2 is C2 alkylene.
